Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $11.04 Analyst target: $37.88 Upside: 243.12%
Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.
See the full interactive analysis & chart →Informational only — not investment advice.